Alvogen Claims Lead On Lenalidomide In Europe
Executive Summary
Alvogen is claiming the first European launch of a generic rival to Revlimid, rolling out the oncology drug in several central and eastern European markets. Meanwhile, IPR challenges to three Revlimid patents in the US have been denied.
You may also be interested in...
Lenalidomide Launch Kicks Off A Year Of Revlimid Competition
Accord has confirmed the launch of a generic lenalidomide rival to Revlimid in the UK. The launch leads off a year that is expected to see the BMS blockbuster also face significant competition elsewhere in Europe and the US.
Accord’s UK Lenalidomide Launch Kicks Off A Year Of Revlimid Competition
Accord has confirmed the launch of a generic lenalidomide rival to Revlimid in the UK. The launch leads off a year that is expected to see the BMS blockbuster also face significant competition elsewhere in Europe and the US.
Last Year’s Winners Build On Successes
Firms that achieved recognition at last year’s Global Generics & Biosimilars Awards have continued to build on that success in the months since.